Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

ClinicalTrials.gov ID: NCT01057901

Public ClinicalTrials.gov record NCT01057901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.

Study identification

NCT ID
NCT01057901
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Enrollment
748 participants

Conditions and interventions

Eligibility (public fields only)

Age range
35 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2010 (Type not available)
Primary completion
Jan 2011 (Actual)
Completion
Jan 2011 (Actual)
Last update posted
Jun 17, 2014

2010 – 2011

United States locations

U.S. sites
84
U.S. states
33
U.S. cities
76
Facility City State ZIP Site status
511.156.01059 Boehringer Ingelheim Investigational Site Birmingham Alabama — —
511.156.01084 Boehringer Ingelheim Investigational Site Tucson Arizona — —
511.156.01053 Boehringer Ingelheim Investigational Site Tuscon Arizona — —
511.156.01069 Boehringer Ingelheim Investigational Site Tuscon Arizona — —
511.156.01063 Boehringer Ingelheim Investigational Site Little Rock Arkansas — —
511.156.01076 Boehringer Ingelheim Investigational Site Little Rock Arkansas — —
511.156.01039 Boehringer Ingelheim Investigational Site Anaheim California — —
511.156.01070 Boehringer Ingelheim Investigational Site Berkeley California — —
511.156.01075 Boehringer Ingelheim Investigational Site La Mesa California — —
511.156.01087 Boehringer Ingelheim Investigational Site Los Angeles California — —
511.156.01064 Boehringer Ingelheim Investigational Site Newport Beach California — —
511.156.01016 Boehringer Ingelheim Investigational Site Oceanside California — —
511.156.01007 Boehringer Ingelheim Investigational Site San Diego California — —
511.156.01038 Boehringer Ingelheim Investigational Site San Diego California — —
511.156.01067 Boehringer Ingelheim Investigational Site Colorado Springs Colorado — —
511.156.01036 Boehringer Ingelheim Investigational Site Denver Colorado — —
511.156.01092 Boehringer Ingelheim Investigational Site Fort Collins Colorado — —
511.156.01027 Boehringer Ingelheim Investigational Site New London Connecticut — —
511.156.01022 Boehringer Ingelheim Investigational Site Coral Gables Florida — —
511.156.01042 Boehringer Ingelheim Investigational Site DeLand Florida — —
511.156.01047 Boehringer Ingelheim Investigational Site Fort Lauderdale Florida — —
511.156.01051 Boehringer Ingelheim Investigational Site Fort Lauderdale Florida — —
511.156.01011 Boehringer Ingelheim Investigational Site Gainseville Florida — —
511.156.01078 Boehringer Ingelheim Investigational Site Lake Worth Florida — —
511.156.01095 Boehringer Ingelheim Investigational Site Orlando Florida — —
511.156.01046 Boehringer Ingelheim Investigational Site Plantation Florida — —
511.156.01056 Boehringer Ingelheim Investigational Site Columbus Georgia — —
511.156.01045 Boehringer Ingelheim Investigational Site Marietta Georgia — —
511.156.01021 Boehringer Ingelheim Investigational Site Roswell Georgia — —
511.156.01081 Boehringer Ingelheim Investigational Site Savannah Georgia — —
511.156.01066 Boehringer Ingelheim Investigational Site Boise Idaho — —
511.156.01025 Boehringer Ingelheim Investigational Site Chicago Illinois — —
511.156.01028 Boehringer Ingelheim Investigational Site Chicago Illinois — —
511.156.01089 Boehringer Ingelheim Investigational Site South Bend Indiana — —
511.156.01010 Boehringer Ingelheim Investigational Site Wichita Kansas — —
511.156.01008 Boehringer Ingelheim Investigational Site Lexington Kentucky — —
511.156.01034 Boehringer Ingelheim Investigational Site New Orleans Louisiana — —
511.156.01012 Boehringer Ingelheim Investigational Site Shreveport Louisiana — —
511.156.01074 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
511.156.01079 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
511.156.01080 Boehringer Ingelheim Investigational Site Haverhill Massachusetts — —
511.156.01006 Boehringer Ingelheim Investigational Site Detroit Michigan — —
511.156.01086 Boehringer Ingelheim Investigational Site Paw Paw Michigan — —
511.156.01005 Boehringer Ingelheim Investigational Site Chaska Minnesota — —
511.156.01013 Boehringer Ingelheim Investigational Site Olive Branch Mississippi — —
511.156.01088 Boehringer Ingelheim Investigational Site Las Vegas Nevada — —
511.156.01001 Boehringer Ingelheim Investigational Site New Brunswick New Jersey — —
511.156.01055 Boehringer Ingelheim Investigational Site Plainsboro New Jersey — —
511.156.01037 Boehringer Ingelheim Investigational Site Poughkeepsie New York — —
511.156.01031 Boehringer Ingelheim Investigational Site Purchase New York — —
511.156.01009 Boehringer Ingelheim Investigational Site The Bronx New York — —
511.156.01024 Boehringer Ingelheim Investigational Site Cary North Carolina — —
511.156.01065 Boehringer Ingelheim Investigational Site Charlotte North Carolina — —
511.156.01029 Boehringer Ingelheim Investigational Site Greensboro North Carolina — —
511.156.01002 Boehringer Ingelheim Investigational Site Raleigh North Carolina — —
511.156.01040 Boehringer Ingelheim Investigational Site Statesville North Carolina — —
511.156.01026 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina — —
511.156.01093 Boehringer Ingelheim Investigational Site Bismarck North Dakota — —
511.156.01052 Boehringer Ingelheim Investigational Site Fargo North Dakota — —
511.156.01017 Boehringer Ingelheim Investigational Site Beachwood Ohio — —
511.156.01032 Boehringer Ingelheim Investigational Site Cincinnati Ohio — —
511.156.01033 Boehringer Ingelheim Investigational Site Cincinnati Ohio — —
511.156.01068 Boehringer Ingelheim Investigational Site Englewood Ohio — —
511.156.01077 Boehringer Ingelheim Investigational Site Ashland Oregon — —
511.156.01072 Boehringer Ingelheim Investigational Site Medford Oregon — —
511.156.01082 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
511.156.01094 Boehringer Ingelheim Investigational Site West Reading Pennsylvania — —
511.156.01083 Boehringer Ingelheim Investigational Site Warwick Rhode Island — —
511.156.01048 Boehringer Ingelheim Investigational Site Anderson South Carolina — —
511.156.01058 Boehringer Ingelheim Investigational Site Greenville South Carolina — —
511.156.01085 Boehringer Ingelheim Investigational Site Watertown South Dakota — —
511.156.01073 Boehringer Ingelheim Investigational Site Bristol Tennessee — —
511.156.01041 Boehringer Ingelheim Investigational Site Chattanooga Tennessee — —
511.156.01035 Boehringer Ingelheim Investigational Site Germantown Tennessee — —
511.156.01091 Boehringer Ingelheim Investigational Site Jackson Tennessee — —
511.156.01060 Boehringer Ingelheim Investigational Site Memphis Tennessee — —
511.156.01003 Boehringer Ingelheim Investigational Site Austin Texas — —
511.156.01054 Boehringer Ingelheim Investigational Site Dallas Texas — —
511.156.01050 Boehringer Ingelheim Investigational Site Fort Worth Texas — —
511.156.01014 Boehringer Ingelheim Investigational Site Houston Texas — —
511.156.01049 Boehringer Ingelheim Investigational Site San Antonio Texas — —
511.156.01015 Boehringer Ingelheim Investigational Site Richmond Virginia — —
511.156.01090 Boehringer Ingelheim Investigational Site Richmond Virginia — —
511.156.01020 Boehringer Ingelheim Investigational Site Seattle Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01057901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2014 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01057901 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →